Literature DB >> 21635907

Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

Corinne Y Ostock1, Kristin B Dupre, Karen L Eskow Jaunarajs, Hannah Walters, Jessica George, David Krolewski, Paul D Walker, Christopher Bishop.   

Abstract

While serotonin 5-HT1A receptor (5-HT1AR) agonists reduce L-DOPA-induced dyskinesias (LID) by normalizing activity in the basal ganglia neurocircuitry, recent evidence suggests putative 5-HT1AR within the primary motor cortex (M1) may also contribute. To better characterize this possible mechanism, c-fos immunohistochemistry was first used to determine the effects of systemic administration of the full 5-HT1AR agonist ±8-OH-DPAT on L-Dopa-induced immediate early gene expression within M1 and the prefrontal cortex (PFC) of rats with unilateral medial forebrain bundle (MFB) dopamine (DA) lesions. Next, in order to determine if direct stimulation of 5-HT1AR within M1 attenuates the onset of LID, rats with MFB lesions were tested for L-Dopa-induced abnormal involuntary movements (AIMs) and rotations following M1 microinfusions of ±8-OH-DPAT with or without coadministration of the 5-HT1AR antagonist WAY100635. Finally, ±8-OH-DPAT was infused into M1 at peak dyskinesia to determine if 5-HT1AR stimulation attenuates established L-Dopa-induced AIMs and rotations. While no treatment effects were seen within the PFC, systemic ±8-OH-DPAT suppressed L-Dopa-induced c-fos within M1. Intra-M1 5-HT1AR stimulation diminished the onset of AIMs and this effect was reversed by WAY100635 indicating receptor specific effects. Finally, continuous infusion of ±8-OH-DPAT into M1 at peak dyskinesia alleviated L-Dopa-induced AIMs. Collectively, these findings support an integral role for M1 in LID and its modulation by local 5-HT1AR.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635907      PMCID: PMC3130088          DOI: 10.1016/j.neuropharm.2011.05.021

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  48 in total

1.  Three-dimensional electrophysiological topography of the rat corticostriatal system.

Authors:  G Glynn; S O Ahmad
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2002-09-24       Impact factor: 1.836

2.  Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.

Authors:  Anna Mura; Matti Mintz; Joram Feldon
Journal:  Exp Neurol       Date:  2002-09       Impact factor: 5.330

3.  In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.

Authors:  Mahmoud M Iravani; Kayhan Tayarani-Binazir; Wing B Chu; Michael J Jackson; Peter Jenner
Journal:  J Pharmacol Exp Ther       Date:  2006-09-07       Impact factor: 4.030

4.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Authors:  M Lundblad; M Andersson; C Winkler; D Kirik; N Wierup; M Angela Cenci
Journal:  Eur J Neurosci       Date:  2002-01       Impact factor: 3.386

Review 5.  Activation of c-fos in the brain.

Authors:  D G Herrera; H A Robertson
Journal:  Prog Neurobiol       Date:  1996-10       Impact factor: 11.685

6.  Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.

Authors:  Sylvia Navailles; Bernard Bioulac; Christian Gross; Philippe De Deurwaerdère
Journal:  Neurobiol Dis       Date:  2010-01-22       Impact factor: 5.996

7.  Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.

Authors:  S Robelet; C Melon; B Guillet; P Salin; L Kerkerian-Le Goff
Journal:  Eur J Neurosci       Date:  2004-09       Impact factor: 3.386

8.  Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding.

Authors:  M Pompeiano; J M Palacios; G Mengod
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

9.  Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Authors:  Christopher Bishop; David M Krolewski; Karen L Eskow; Christopher J Barnum; Kristin B Dupre; Terrence Deak; Paul D Walker
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

10.  Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  C Marin; E Aguilar; M C Rodríguez-Oroz; G D Bartoszyk; J A Obeso
Journal:  Psychopharmacology (Berl)       Date:  2009-01-22       Impact factor: 4.530

View more
  19 in total

1.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

Review 2.  Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.

Authors:  David Lindenbach; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2013-10-07       Impact factor: 8.989

3.  Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.

Authors:  Jan Rusz; Cecilia Bonnet; Jiří Klempíř; Tereza Tykalová; Eva Baborová; Michal Novotný; Aaron Rulseh; Evžen Růžička
Journal:  J Neurol       Date:  2015-02-17       Impact factor: 4.849

Review 4.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

Review 5.  Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Christopher Bishop
Journal:  J Neural Transm (Vienna)       Date:  2018-01-05       Impact factor: 3.575

6.  Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following L-DOPA Administration in Hemi-Parkinsonian Rats.

Authors:  Adrian Newman-Tancredi; Mark A Varney; Andrew C McCreary
Journal:  Neurochem Res       Date:  2018-03-23       Impact factor: 3.996

7.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

8.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

9.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

10.  The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.

Authors:  David Lindenbach; Melissa M Conti; Corinne Y Ostock; Jessica A George; Adam A Goldenberg; Mitchell Melikhov-Sosin; Emily E Nuss; Christopher Bishop
Journal:  J Neurosci       Date:  2016-09-21       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.